uchenne muscular dystrophy (DMD) is a rare, inherited neuromuscular disorder. Methods: To describe the clinical characteristics and healthcare resource utilization (HCRU) of male patients with DMD in commercial and Medicaid cohorts, this retrospective study identified male patients in the Truven Health MarketScan ® Commercial and Medicaid databases diagnosed with hereditary progressive muscular dystrophy (HPMD) presumed to have DMD between 2011-2014. Patients with ≥2 medical claims with a diagnosis for HPMD (International Classification of Diseases, 9th revision, Clinical Modification: 359.1) were included. Patients were followed for 12 months after diagnosis date, during which clinical characteristics and HCRU were assessed. Results: In total, 2,285 patients met the selection criteria. In these patients, corticosteroid and anti-infective agents were commonly utilized. Physician office visits were extremely common, with over 70% of all patients having at least one visit. Wheelchairs were commonly used, with the incidence of use increasing with age. Mechanical ventilators and airway clearance devices were underrepresented in the data. Conclusion: Patients with DMD had higher annual HCRU costs when compared with a non-DMD age-matched cohort, with patients in commercial cohorts having a higher annual average cost than those in Medicaid cohorts.
US NEUROLOGY
In this study, patients were required to have at least two diagnoses for HPMD (ICD-9-CM: 359.1) between September 30, 2011 and September 30, 2014, and the diagnoses had to be within 18 months of each other. The first captured diagnosis could not be based on a laboratory claim, and patients were required to have at least 12 months of continuous health plan enrollment with pharmacy benefits following the date of the first DMD diagnosis. As DMD is the most common form of muscular dystrophy to affect children and because onset of disease is most often between the ages of three and five, 1, 6 patients aged 6-25 on their first captured diagnosis were included to assess disease-related costs across the full spectrum of patients with DMD; the cohort was restricted to males as DMD is an X-linked recessive condition. 5 
Study design
A retrospective, observational cohort design was used to describe male patients presumed to have DMD who were identified in an administrative claims database. From this cohort, patients were stratified based on age at first captured diagnosis of DMD during the study period, into mutually exclusive categories of males aged 6-10, 11-14, 15-18, and 19-25 years of age. Clinical characteristics, treatment patterns, and healthcare resource utilization were assessed in the 12 months following the diagnosis date.
Average utilization and costs were calculated for the calendar year 2014 for a subset of the overall cohort with full benefit coverage during that calendar 
Results

Study sample characteristics
A total of 2,285 patients were presumed to have DMD in our study sample, US NEUROLOGY cohort 6-10 year age group and 20.6% of patients in the commercial cohort 19-25 year age group with DMD. Corticosteroid use was just over 43% in the youngest commercial cohort age group, but fell to 13.7% in the 15-18 age group. Anti-infective use was common among all DMD age cohorts, and increased from the 6-10 to 19-25 year age groups (11.0-27.2% in the commercial cohort, 15.3-25.0% in the Medicaid cohort).
At least 25% of patients in all age groups, in both the commercial cohort and Medicaid cohort, had at least one claim in the emergency department.
In the Medicaid cohort, 73.3-85% of patients had a claim for a physician office visit, while home nursing services were utilized by a lower proportion of patients in the commercial cohort (6-20% commercial versus 22-37% Medicaid 
*Deflazacort is not currently available in the US through prescription pharmacies; this analysis does not include this medication. Full corticosteroid list can be found in Appendix C.
Patient counts are reported as 'N (%)', averages are reported as 'mean (SD)'. DMD = Duchenne muscular dystrophy; N = number of patients; SD = standard deviation.
Discussion DMD is a rare, X-linked recessive disorder that disproportionately affects males. 4 Disease burden can be accelerated as physical symptoms begin as young as 3 years of age. As DMD is incurable, affected patients frequently utilize medical devices to assist in disease management, as well as supportive medication such as corticosteroids and anti-infective agents.
Corticosteroids have been found to maintain muscle strength and prolong ambulation, even preserving upper limb strength after loss of ambulation. 2 This manuscript sought to describe utilization practices and disease morbidity based on a review of a large medical database. A number of trends were seen and are described below.
As expected, many patients were on corticosteroids, the utilization on which declined with age after 13 years of age, roughly corresponding with the age at which most patients lose ambulation. Corticosteroids were seen in a Airway clearance is of critical importance to patients with DMD, particularly in advanced disease stages when respiratory muscles become compromised. 12, 13 Though intubation is necessary in a majority of patients with DMD in time, use of mechanical percussive devices is effective in delaying this step. [14] [15] [16] In this analysis, we found documented utilization of mechanical cough assist devices in database claims to be surprisingly low. The reasons for this may be four-fold: first, this study captured utilization claims for 1 year after the patient's first captured diagnosis within our study period; it is possible that patients obtained a cough assist device following a previous, uncaptured DMD diagnosis if said diagnosis was outside our timeframe; second, as previously mentioned, our data is composed of administrative medical and pharmacy claims, if patients do not obtain their cough assist device through their insurance carrier, it will not be captured in our analysis; third, physician variability in prescribing practices may influence utilization of devices among patients; fourth, there may be data coding limitations we are not aware of that confines our analysis.
Other literature sources describing utilization of cough assist devices are scarce, as respiratory care for patients with neuromuscular disease has improved dramatically over the last decade. The few studies that examine ventilation use rates are limited to single-institution studies and rely on retrospective medical chart analysis, as is seen in McKim et al. 2013 . 16 This underrepresentation of cough assist devices in the data highlights the need for continued research, especially given the updated speed at which data are now available, which can assist in assessing the full burden of disease in patients with DMD in the real-world. While the average healthcare cost was highest in the 11-14 year old age group, hospital admissions were most frequent in the older age groups. progression. The present study shows lower costs in the youngest age group, with increased costs in older patients. More research is needed to accurately identify cost-driving factors in patients with DMD that can explain the cost discrepancy among age groups.
Certain limitations of the study design are inherent in any retrospective, administrative claims-based cohort study. Identifying patients with DMD based on the presence of ICD-9-CM diagnosis codes recorded on medical claims may be imprecise, particularly considering the current study cohort. A specific ICD-9-CM diagnosis code does not exist for DMD and therefore male patients with other muscular dystrophies could have been included in these analyses; a number of restrictions were used during patient selection to estimate the DMD population including age and gender restrictions.
Our results may underestimate costs, as DMD may be under coded. Only those prescriptions that have been filled are available in our database. As treatment options for patients with DMD continue to improve with medical advances, extending patient life expectancy will allow for the ability to accurately describe the real-world utilization and outcomes of these treatments. The cumulative cost of these medications and equipment is substantially higher than in the unaffected population and clearly represents a large financial burden that goes along with the burden on quality of life of the patient with DMD.
